Keywords: Gilead Sciences, Research update, Hepatitis C, GS-5885, Sofosbuvir

Gilead Sciences updates on hepatitis C development programs

Article | 07 January 2013

US biotech firm Gilead Sciences (Nasdaq: GILD) presented several updates regarding its late-stage pipeline candidates for the treatment of chronic ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Gilead Sciences

Go to company listing

Related Drugs

sofosbuvir

GS-5885

Go to drug listing